Duke logo

ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out what effects (good and/or bad) the study drug XL184 has on your tumor or type of cancer.

We also want to learn more about how XL184 works against cancer cells and other immune cells.

What is the Condition Being Studied?

Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Who Can Participate in the Study?

Children and adults who:
-Are age 2-30 years old
-Have recurrent or refractory disease, or newly diagnosed disease with rare tumor type
-Have fully recovered from previous chemo, immunotherapy or radiotherapy

Age Group
Adults, Children

What is Involved?

If you choose to join this study you will:
- Get the study drug XL 184 daily during each cycle
-- Each cycle lasts 28 days
- Get tests and imaging scans to monitor tumor changes

Study Details

Full Title
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator
Pediatric Hematology-Oncology Specialist
Protocol Number
IRB:PRO00084400
NCT:NCT02867592
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698